Drug intelligence / Profile preview

Magnogene

Development stage
Phase 4
Lead developer
Sanofi
Modality
Small Molecules
Administration
Oral
01

Overview

Magnogene is a pharmaceutical product primarily composed of magnesium bromide hexahydrate, historically utilized as a neurosedative and for the correction of magnesium deficiency. As a source of magnesium, it provides an essential mineral cofactor involved in over 300 enzymatic reactions, including those responsible for energy metabolism and protein synthesis. The magnesium ion serves as a physiological antagonist of the N-methyl-D-aspartate (NMDA) receptor and a natural calcium channel blocker, which contributes to its neuro-stabilizing and muscle-relaxant properties. The bromide component historically provided additional central nervous system depressant effects by enhancing GABAergic inhibitory neurotransmission. While indicated for conditions such as neuromuscular irritability, spasmophilia, and mild anxiety, its clinical use has largely been superseded by other magnesium salts and modern sedative-hypnotics due to the risk of bromide accumulation and associated toxicity.

Brand names
Magnogene
Other names
magnesium bromidemagnesium bromide hexahydratedibromure de magnésium
02

Targets

GABAA (Gamma-aminobutyric acid receptor)CaV (Voltage-gated calcium channel protein complex)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on Magnogene.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Magnogene.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call